type 2 diabetes – Medxy AI

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling

By MedXY 09/23/2026

This study uses longitudinal modeling to compare tirzepatide and semaglutide’s effects on fasting glucose in type 2 diabetes, revealing tirzepatide’s superior control largely due to greater insulin-independent hepatic glucose production suppression.

Cardiology Diabetes & Endocrinology news

Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World Study

By MedXY 09/23/2026

Empagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced absolute benefits in those with existing cardiovascular disease.

Diabetes & Endocrinology news Respiratory

GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort Study

By MedXY 09/20/2026

A comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.

Diabetes & Endocrinology news Ophthalmology

Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World Data

By MedXY 09/18/2026

Fenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.

Diabetes & Endocrinology Gastroenterology news

Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative Analysis

By MedXY 09/15/2026

Among type 2 diabetes patients using GLP-1 receptor agonists, oxycodone is linked to higher short-term risks of severe gastrointestinal complications compared to hydrocodone and tramadol, warranting cautious opioid selection in this population.

Diabetes & Endocrinology news Ophthalmology

Common Anti-Inflammatory Drugs Linked to Lower Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes

By MedXY 09/14/2026

A large retrospective cohort study suggests that cetirizine, ibuprofen, and prednisone use in adults with type 2 diabetes is associated with significantly reduced incidence of diabetic macular edema and proliferative diabetic retinopathy, highlighting anti-inflammatory pathways as potential targets for prevention.

Diabetes & Endocrinology news OB/GYN & Women's Health

Linking Female Infertility History to Type 2 Diabetes Risk: Insights from the Nurses’ Health Study II

By MedXY 09/06/2026

This study explores the increased risk of type 2 diabetes among women with a history of infertility, highlighting specific infertility causes and implications independent of BMI.

Diabetes & Endocrinology news Public Health

Sarcopenic Obesity and Type 2 Diabetes Risk: Insights from the UK Biobank Study

By MedXY 09/06/2026

This study reveals sarcopenic obesity significantly increases the risk of incident type 2 diabetes, exceeding risks from obesity or sarcopenia alone, highlighting the importance of combined muscle and adiposity assessment in diabetes prevention.

Diabetes & Endocrinology news

Decoding Pancreatic Islet Single-Cell Transcriptomic Diversity Across Type 2 Diabetes Subtypes

By MedXY 09/04/2026

Single-cell RNA sequencing of pancreatic islets reveals distinct molecular signatures linked to specific clinical subtypes of type 2 diabetes, highlighting the heterogeneous pathophysiology and providing potential subtype-specific therapeutic targets.

Diabetes & Endocrinology news

Ketoacidosis Risk with SGLT2 Inhibitors in Type 2 Diabetes: Insights from a Scandinavian Cohort Study

By MedXY 09/04/2026

A large Scandinavian study reveals that ketoacidosis risk during SGLT2 inhibitor therapy in type 2 diabetes varies by patient factors and persists beyond early treatment, highlighting the need for ongoing risk assessment and management strategies.

Diabetes & Endocrinology Internal Medicine news

Impact of the DASH4D Diet on Glycemic Biomarkers in Adults with Type 2 Diabetes: Insights from a Randomized Controlled Feeding Trial

By MedXY 08/30/2026

The DASH4D diet, a tailored DASH-style intervention for diabetes, significantly improved key glycemic biomarkers including fructosamine, fasting glucose, and HbA1c compared to a typical American diet in adults with type 2 diabetes.

Diabetes & Endocrinology news

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial

By MedXY 08/26/2026

This phase 2b trial evaluates bofanglutide's efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.

Diabetes & Endocrinology news

GLP1R R131Q Variant: A Genetic Key to Preserving β-Cell Function and Enhancing GLP-1RA Efficacy in Type 2 Diabetes

By MedXY 08/26/2026

The gain-of-function GLP1R R131Q variant slows β-cell decline and improves glycemic response to GLP-1 receptor agonists, highlighting its potential role in precision diabetes therapeutics.

Diabetes & Endocrinology news

HTD1801 Monotherapy Significantly Improves Glycemic Control and Cardiometabolic Health in Type 2 Diabetes: Results From a 56-Week Phase 3 Trial

By MedXY 08/25/2026

A phase 3 trial demonstrated that HTD1801 monotherapy significantly reduces HbA1c and improves cardiometabolic and inflammatory markers in patients with inadequately controlled type 2 diabetes, with sustained effects and a favorable safety profile over 56 weeks.

Diabetes & Endocrinology Neurology news

Distinct Complication Patterns in Lean Versus Overweight African Adults with Type 2 Diabetes: Implications for Targeted Management

By MedXY 08/24/2026

African adults with type 2 diabetes who are lean exhibit distinct complication profiles characterized by higher retinopathy and stroke risk but lower hypertension and cardiovascular disease risk compared to their overweight/obese counterparts, indicating a unique diabetes phenotype requiring tailored treatment approaches.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Gestational Diabetes Mellitus: Ethnic Variations in Recurrence and Long-Term Type 2 Diabetes Risk

By MedXY 08/22/2026

This study highlights the high recurrence of gestational diabetes mellitus (GDM) and its strong association with future type 2 diabetes, particularly among Asian women, underscoring the need for ethnicity-specific prevention and screening strategies.

Cardiology Diabetes & Endocrinology news

suPAR as a Novel Marker for Residual Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes with Coronary Artery Disease

By MedXY 08/21/2026

In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR's potential in identifying treatment-resistant inflammation and refining cardiovascular risk stratification.

Diabetes & Endocrinology news

Long-term Safety of Oral Orforglipron in Japanese Patients with Type 2 Diabetes (ACHIEVE-J): A Multicenter, Randomized, Open-label, Phase 3 Trial

By MedXY 08/18/2026

This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.

Diabetes & Endocrinology news Otorhinolaryngology

Exploring the Link Between GLP-1 Receptor Agonists and Sensory Disturbances in Diabetes Care

By MedXY 08/17/2026

This study reveals a significant association between GLP-1 receptor agonist therapy and increased risk of smell and taste disturbances in type 2 diabetes patients, highlighting the need for awareness and monitoring.

Clinical Updates Diabetes & Endocrinology news Public Health

Medicare Advantage and Type 2 Diabetes Outcomes: Evaluating Clinical and Social Impacts Amid Rising Costs

By MedXY 08/15/2026

Medicare Advantage (MA) shows no significant improvement over original Medicare (OM) in managing type 2 diabetes outcomes or mitigating related social needs despite higher costs, underscoring the need for effective spending strategies.